Discovery, characterization, and clinical development of the glucagon-like peptides
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Discovery, characterization, and clinical development of the glucagon-like peptides. / Drucker, Daniel J; Habener, Joel F; Holst, Jens Juul.
I: The Journal of Clinical Investigation, Bind 127, Nr. 12, 01.12.2017, s. 4217-4227.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Discovery, characterization, and clinical development of the glucagon-like peptides
AU - Drucker, Daniel J
AU - Habener, Joel F
AU - Holst, Jens Juul
PY - 2017/12/1
Y1 - 2017/12/1
N2 - The discovery, characterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years and includes contributions from multiple investigators, science recognized by the 2017 Harrington Award Prize for Innovation in Medicine. Herein, we provide perspectives on the historical events and key experimental findings establishing the biology of GLP-1 as an insulin-stimulating glucoregulatory hormone. Important attributes of GLP-1 action and enteroendocrine science are reviewed, with emphasis on mechanistic advances and clinical proof-of-concept studies. The discovery that GLP-2 promotes mucosal growth in the intestine is described, and key findings from both preclinical studies and the GLP-2 clinical development program for short bowel syndrome (SBS) are reviewed. Finally, we summarize recent progress in GLP biology, highlighting emerging concepts and scientific insights with translational relevance.
AB - The discovery, characterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years and includes contributions from multiple investigators, science recognized by the 2017 Harrington Award Prize for Innovation in Medicine. Herein, we provide perspectives on the historical events and key experimental findings establishing the biology of GLP-1 as an insulin-stimulating glucoregulatory hormone. Important attributes of GLP-1 action and enteroendocrine science are reviewed, with emphasis on mechanistic advances and clinical proof-of-concept studies. The discovery that GLP-2 promotes mucosal growth in the intestine is described, and key findings from both preclinical studies and the GLP-2 clinical development program for short bowel syndrome (SBS) are reviewed. Finally, we summarize recent progress in GLP biology, highlighting emerging concepts and scientific insights with translational relevance.
KW - Animals
KW - Diabetes Mellitus, Type 2
KW - Drug Discovery
KW - Glucagon-Like Peptide 1
KW - Glucagon-Like Peptide 2
KW - Glucagon-Like Peptide-1 Receptor
KW - Humans
KW - Short Bowel Syndrome
KW - Structure-Activity Relationship
KW - Journal Article
KW - Review
U2 - 10.1172/JCI97233
DO - 10.1172/JCI97233
M3 - Review
C2 - 29202475
VL - 127
SP - 4217
EP - 4227
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
SN - 0021-9738
IS - 12
ER -
ID: 189623179